How to identify new targets and indications for aging drug development

Phil Newman

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Simon Melov

Professor, Buck Institute and Founder and CEO, Gerostate Alpha

How to identify new targets and indications for aging drug development

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Variant Bio extends AI genetics deal to the heart

Sava raises $36m as glucose sensor deal takes shape

The regulatory door is ajar

Genentech pays $100m upfront for Alector’s AL050

Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy

Perplexity enters the consumer health AI arena

Startup targets ‘untreatable blindness’ with bionic eye system

Science Corp lands $230m to commercialize vision restoration chip

MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity

How to identify new targets and indications for aging drug development

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Simon Melov

Professor, Buck Institute and Founder and CEO, Gerostate Alpha

How to identify new targets and indications for aging drug development

You might also like

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Sava raises $36m as glucose sensor deal takes shape

The regulatory door is ajar

Genentech pays $100m upfront for Alector’s AL050

Perplexity enters the consumer health AI arena

Startup targets ‘untreatable blindness’ with bionic eye system

Science Corp lands $230m to commercialize vision restoration chip

Ergothioneine: The little-known molecule transforming brain health and longevity

COGNITION: FLT’s new brain-boosting supplement that’s redefining mental performance

7 Best l-glutamine supplements to buy in 2024

Macau team uses TCM to crack XPRIZE’s top 10

EU longevity strategy gains political momentum

The case for regeneration over slowing decline

How to identify new targets and indications for aging drug development

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Simon Melov

Professor, Buck Institute and Founder and CEO, Gerostate Alpha

How to identify new targets and indications for aging drug development

You might also like

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE